Studies have shown that TIM-3 is highly expressed on LSC but not or lowly expressed on normal hematopoietic stem cells (HSC), and that blocking TIM-3 not only slows down the leukemic progression in AML mice, but also reduces the number of leukemic stem cells transplanted into mice (22). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.